Xavier Nogués Solán, Monica Payés Peich, Lidia García Gibert

Research output: Contribution to journalReview articleResearchpeer-review


Teriparatide is considered the first anabolic drug to treat established osteoporosis. Intermittent administration of PTH leads to cAMP presence that produces proliferation and differentiation of progenitors. Teriparatide, a 1-34 PTH fragment, has demonstrated in several studies in postmenopausal women, men osteoporosis and corticosteroid-induced osteoporosis its efficacy to treat osteoporosis. The risk of having a new vertebral fracture decreases between 65% to 69%, and the increase of bone mass ranges between 9% to 11%. This is similar to the range reached by bisphosphonates as alendronate and risedronate at 7 years of treatment. Moreover, recent studies have shown that a secuential treatment with bisphosphonates and teriparatide the increase of bone mass reaches 23,6%. The prescription of teriparatide in Spain is only for postmenopausal establish osteoporosis, that means with fractures.
Original languageEnglish
Pages (from-to)96-103
JournalSeminarios de la Fundacion Espanola de Reumatologia
Issue number2
Publication statusPublished - 1 Jan 2006


  • Bone mass
  • Fracture
  • Osteoporosis
  • PTH
  • Teriparatide


Dive into the research topics of 'Teriparatide'. Together they form a unique fingerprint.

Cite this